benphothiamine has been researched along with Asymmetric Diabetic Proximal Motor Neuropathy in 26 studies
benfotiamine : A thioester that is a synthetic analogue of thiamine obtained by acylative cleavage of the thiazole ring and O-phospohorylation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-five diabetes patients with painful peripheral polyneuropathy were enrolled in a 3-month observational study comparing the therapeutic efficacy of Milgamma tablets (50 mg benfothiamine and 0." | 5.08 | Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy. ( Mincheva, L; Mitkov, M; Pavlova, M; Simeonov, S; Troev, D, 1997) |
| " Currently, there are only few pathogenetically oriented pharmacotherapies for DSPN, one of which is benfotiamine, a prodrug of thiamine with a high bioavailability and favourable safety profile." | 3.11 | BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. ( Al-Hasani, H; Bönhof, GJ; Herder, C; Icks, A; Knebel, B; Kuss, O; Reule, C; Roden, M; Sipola, G; Strassburger, K; Strom, A; Wollmann, JC; Ziegler, D, 2022) |
| "In people with Type 2 diabetes and markedly impaired fasting flow-mediated dilatation, a mixed test meal does not further deteriorate flow-mediated dilatation or variables of microvascular or autonomic nervous function." | 2.78 | A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes. ( Pop, A; Stirban, A; Tschoepe, D, 2013) |
| "165 patients with symmetrical, distal diabetic polyneuropathy were randomised to one of three treatment groups entering the wash-out phase and 133/124 patients were analysed in the ITT/PP analysis: Benfotiamine 600 mg per day (n=47/43), benfotiamine 300 mg per day (n=45/42) or placebo (n=41/39)." | 2.73 | Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. ( Achenbach, U; Bretzel, RG; Federlin, K; Gaus, W; Stracke, H, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (19.23) | 18.2507 |
| 2000's | 10 (38.46) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bönhof, GJ | 1 |
| Sipola, G | 1 |
| Strom, A | 1 |
| Herder, C | 1 |
| Strassburger, K | 1 |
| Knebel, B | 1 |
| Reule, C | 1 |
| Wollmann, JC | 1 |
| Icks, A | 1 |
| Al-Hasani, H | 1 |
| Roden, M | 1 |
| Kuss, O | 1 |
| Ziegler, D | 2 |
| Stirban, OA | 1 |
| Zeller-Stefan, H | 1 |
| Schumacher, J | 1 |
| Gaus, W | 2 |
| Schuerholz, T | 1 |
| Pop-Busui, R | 1 |
| Várkonyi, T | 2 |
| Körei, A | 1 |
| Putz, Z | 1 |
| Martos, T | 1 |
| Keresztes, K | 1 |
| Lengyel, C | 1 |
| Nyiraty, S | 1 |
| Stirban, A | 2 |
| Jermendy, G | 1 |
| Kempler, P | 6 |
| Zhuravleva, MV | 1 |
| Shikh, EV | 1 |
| Makhova, AA | 1 |
| Pop, A | 1 |
| Tschoepe, D | 1 |
| Sergienko, VA | 1 |
| Segin, VB | 1 |
| Samir, A | 1 |
| Sergienko, AA | 1 |
| Zhu, Z | 1 |
| Varadi, G | 1 |
| Carter, SG | 1 |
| Winkler, G | 2 |
| Haupt, E | 1 |
| Ledermann, H | 1 |
| Köpcke, W | 1 |
| Nakamura, J | 1 |
| Medvedeva, LA | 1 |
| Gnezdilov, AV | 1 |
| Zagorul'ko, OI | 1 |
| Syrovegin, AV | 1 |
| Samoĭlova, NV | 1 |
| Slashchuk, IuI | 1 |
| Wernicke, JF | 1 |
| Wang, F | 1 |
| Pritchett, YL | 1 |
| Smith, TR | 1 |
| Raskin, J | 1 |
| D'Souza, DN | 1 |
| Iyengar, S | 1 |
| Chappell, AS | 1 |
| Stracke, H | 2 |
| Achenbach, U | 1 |
| Federlin, K | 2 |
| Bretzel, RG | 1 |
| Lindemann, A | 1 |
| Simeonov, S | 1 |
| Pavlova, M | 1 |
| Mitkov, M | 1 |
| Mincheva, L | 1 |
| Troev, D | 1 |
| Sadekov, RA | 1 |
| Danilov, AB | 1 |
| Veĭn, AM | 1 |
| Pál, B | 1 |
| Nagybéganyi, E | 1 |
| Ory, I | 1 |
| Porochnavec, M | 1 |
| Balabolkin, MI | 1 |
| Kreminskaia, VM | 1 |
6 reviews available for benphothiamine and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
Advances in the management of diabetic neuropathy.
Topics: Adjuvants, Immunologic; Amines; Anticonvulsants; Antidepressive Agents; Antioxidants; Cardiovascular | 2017 |
[A relationship between analgesic and neurotropic effects by the example of milgamma].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Cytochrome P-450 Enzyme System; Diabetic | 2012 |
[Pathomechanism of diabetic neuropathy: background of the pathogenesis-oriented therapy].
Topics: Adjuvants, Immunologic; Antioxidants; Blood Vessels; Diabetic Neuropathies; Hexosamines; Humans; Oxi | 2010 |
[Treatment of neuropathies].
Topics: Adjuvants, Immunologic; Capsaicin; Diabetic Neuropathies; Diagnosis, Differential; Humans; Liver Dis | 2004 |
[Development of therapeutic agents for diabetic neuropathies].
Topics: Aldehyde Reductase; Antioxidants; C-Peptide; Diabetic Neuropathies; Drug Design; Enzyme Inhibitors; | 2005 |
Diabetic neuropathy: new strategies for treatment.
Topics: Aldehyde Reductase; Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Antioxidants; Cycloh | 2008 |
11 trials available for benphothiamine and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Humans; Polyneuropathies; Qua | 2022 |
Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: A double-blind, randomized, placebo-controlled, parallel group pilot study over 12 months.
Topics: Diabetes Mellitus; Diabetic Neuropathies; Double-Blind Method; Humans; Pilot Projects; Polyneuropath | 2020 |
A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes.
Topics: Adult; Aged; Antioxidants; Autonomic Pathways; Biomarkers; Blood Glucose; Cross-Over Studies; Diabet | 2013 |
Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2005 |
[Neurometabolic therapy of diabetic neuropathy].
Topics: Adjuvants, Immunologic; Analgesics, Non-Narcotic; Antioxidants; Blood Glucose; Carbamazepine; Diabet | 2006 |
An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
Topics: Acetaminophen; Amitriptyline; Analgesics; Carbamazepine; Diabetes Complications; Diabetic Neuropathi | 2007 |
Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.
Topics: Adjuvants, Immunologic; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic | 2008 |
A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.
Topics: Administration, Oral; Aged; Capsules; Diabetic Neuropathies; Double-Blind Method; Drug Combinations; | 1996 |
Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy.
Topics: Adult; Aged; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Pain; Thiamine; Vitamin B 12; | 1997 |
[Diabetic polyneuropathy treatment by milgamma-100 preparation].
Topics: Adult; Chelating Agents; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination | 1998 |
Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy.
Topics: Adult; Aged; Blood Glucose; Chelating Agents; Cholesterol; Diabetic Neuropathies; Female; Glycated H | 1999 |
9 other studies available for benphothiamine and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
[The effect of long-chain polyunsaturated higher ω-3 fatty acids, benfotiamine and α-lipoic acid on the lipid metabolism in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy].
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; D | 2013 |
Pharmacokinetics of the transdermal delivery of benfotiamine.
Topics: Administration, Cutaneous; Animals; Diabetic Neuropathies; Drug Delivery Systems; Guinea Pigs; Male; | 2016 |
[Treatment of neuropathies].
Topics: Adjuvants, Immunologic; Adrenergic Uptake Inhibitors; Amines; Analgesics; Antioxidants; Capsaicin; C | 2010 |
[Diabetic neuropathies and angiopathies. Compensating for thiamine deficiency].
Topics: Adjuvants, Immunologic; Diabetic Angiopathies; Diabetic Neuropathies; Humans; Thiamine; Thiamine Def | 2010 |
[Prevention of complications in diabetes mellitus. Interdisciplinary collaboration to control sequelae].
Topics: Adjuvants, Immunologic; Animals; Cooperative Behavior; Cross-Sectional Studies; Diabetes Complicatio | 2011 |
[Oral benfotiamine therapy. Thus you protect the nerves of diabetic patients].
Topics: Administration, Oral; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Melli | 2004 |
Benfotiamine. Monograph.
Topics: Alcoholic Neuropathy; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Humans; | 2006 |
[The effectiveness of the neurotropic agents: benfotiamin combinations].
Topics: Adjuvants, Immunologic; Diabetic Neuropathies; Humans; Thiamine | 1995 |
[Diabetic neuropathy].
Topics: Acupuncture Therapy; Adjuvants, Immunologic; Antioxidants; Combined Modality Therapy; Diabetic Neuro | 2000 |